SCHEMBL6076618

SCHEMBL6076618

Oc1nc(-c2ccc(Cl)c(Cl)c2)nc2c1CCCC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
EEF2K O00418 1/20 0.43
HPGD P15428 2/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ACHE P22303 3/20 0.40
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 1/20 0.37
AHR P35869 1/20 0.37
PIK3CA P42336 1/20 0.36
TP53 P04637 1/20 0.36
SLC6A3 Q01959 2/20 0.36
SLC6A2 P23975 1/20 0.36
BCHE P06276 2/20 0.36
HRH4 Q9H3N8 1/20 0.36
PGR P06401 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6076353 0.85 NPC1 (0.47) NPC1RAB9AEEF2KHPGDALDH1A1
SCHEMBL6075338 0.83 TP53 (0.49) NPC1RAB9AEEF2KHPGDALDH1A1
SCHEMBL6075784 0.81 PDE4B (0.47) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL4809314 0.80 TP53 (0.46) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL6075799 0.80 ACHE (0.40) HPGDALDH1A1ACHEKDM4ETP53
SCHEMBL5734396 0.78 PDE4B (0.47) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL6075610 0.77 MAPK1 (0.52) HPGDALDH1A1MAPTACHEKDM4E
SCHEMBL6075839 0.77 KDM4E (0.44) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL5733680 0.77 ACHE (0.40) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL27013361 0.76 LMNA (0.56) ALDH1A1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7045526-B2 Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-05-16 US disclosed
US-20040063690-A1 Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2004-04-01 US disclosed
US-6660746-B1 Cardiovascular disorders AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-12-09 US disclosed
EP-1150963-B1 SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AVENTIS PHARMA GMBH (DE) 2003-12-03 EP disclosed
EP-1150963-A1 SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Aventis Pharma Deutschland GmbH (DE) 2001-11-07 EP disclosed
WO-2000046214-A1 SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063690-A1 Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them PDE3A, PDE2A, PDE3B NPC1 1260/4885RAB9A 1596/4885EEF2K 1141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.